Safety and Tumor Responses With Lambrolizumab (Anti–PD-1) in Melanoma
New England Journal of Medicine - United States
doi 10.1056/nejmoa1305133
Full Text
Open PDFAbstract
Available in full text
Categories
Date
July 11, 2013
Authors
Publisher
Massachusetts Medical Society